Facial features analyzed from 3D photographs could predict the likelihood of having obstructive sleep apnea

0
412

Facial features analyzed from 3D photographs could predict the likelihood of having obstructive sleep apnea, according to a study published in the April issue of the Journal of Clinical Sleep Medicine.

Using 3D photography, the study found that geodesic measurements – the shortest distance between two points on a curved surface – predicted with 89 percent accuracy which patients had sleep apnea.

Using traditional 2D linear measurements alone, the algorithm’s accuracy was 86 percent.

“This application of the technique used predetermined landmarks on the face and neck,” said principle investigator Peter Eastwood, who holds a doctorate in respiratory and sleep physiology and is the director of the Centre for Sleep Science at the University of Western Australia (UWA).

“Geodesic and linear distances between these landmarks were determined, and a linear discriminant algorithm was trained, tested and used to classify an individual as being at high or low risk of having obstructive sleep apnea.”

The study involved 300 individuals with varying severity levels of sleep apnea and 100 people without sleep apnea.

These individuals came from a local hospital and from the Raine Study, a longitudinal cohort study in Western Australia.

All underwent overnight sleep studies and took 3D photos with a craniofacial scanner system. Data were used to build a predictive algorithm that was tested on another patient set.

Eastwood worked with Syed Zulqarnain Gilani, a computer scientist at UWA to identify the facial features most commonly associated with sleep apnea as neck width and degree of retrusion of the lower jaw (retrognathia), but the study also uncovered other possible indicators.

“The data obtained from the present study indicate that other measurements such as width and length of the lower jaw, width of the face, and distance between the eyes also contribute to distinguishing individuals with and without OSA,” he said.

In a related commentary, also published in the April issue of JCSM, Drs. Ofer Jacobowitz and Stuart MacKay indicated that they see a bright future for 3D photography as a screening tool, potentially combined with data from a patient’s digital health tracker and health history.

“Certain wearable devices are already capable of measuring pulse oximetry and some provide oximetry variability analysis,” they wrote.

“Likewise, the home of tomorrow will likely incorporate sensors in the bedroom which may gather physiological sleep data using optical, acoustic, infrared, ultrasonographic or other means.”

According to Eastwood, existing studies show a genetic predisposition to sleep apnea, and facial structure is a significant component of such predisposition, leading researchers to seek an accessible, affordable method of screening based on facial characteristics.

Eastwood believes that 3D facial photography could represent the first, inexpensive, widely available screening tool for sleep apnea.

“OSA is a huge public health problem, and despite effective treatments being available, many with OSA are currently undiagnosed,” said Eastwood. “Therefore, simple, accurate screening tools are needed to predict those who have OSA.”


Epidemiology of obstructive sleep apnoea

The most prevalent form of sleep disordered breathing in industrialised societies is obstructive sleep apnoea (OSA) [1]. OSA is characterised by repetitive collapses (apnoeas) or near collapses (hypopnoeas) of the upper airway during sleep, resulting in intermittent hypoxaemia and increased sympathetic arousal.

When symptoms of daytime dysfunction and other neurological impairment are directly attributed to the apnoeas and hypopnoeas in sleep, the disorder is known as obstructive sleep apnoea/hypopnoea syndrome (OSAHS) [1–3]. The apnoea–hypopnoea index (AHI) can be used to assess severity of the sleep disorder when an electroencephalographic measure of sleep is available.

Daytime sleepiness is usually recorded by a thorough clinical history, but is also frequently recorded in both practice and in research studies using the Epworth Sleepiness Scale (ESS) [4]; a score of ≥11 out of 24 is considered consistent with excessive daytime sleepiness. Unfortunately, the ESS does not correlate well with objective measures of daytime sleepiness [5].

Thus, the epidemiology of OSA and OSAHS can vary significantly in the population depending on definitions used for the nocturnal breathing pauses and any resulting daytime sleepiness/impairment. Additionally, the prevalence of sleep disordered breathing will vary according to age and sex [1–3].

The most frequently cited study in respect of OSA and OSAHS prevalence in a mostly white, mid-American cohort of people demonstrated that 24% of males (n=325) and 9% of females (n=250) had an AHI ≥5 events·h−1 of sleep [6].

However, when sleepiness was factored in as causally related to the AHI, the prevalence fell to 4% in males and 2% in females. Several population prevalence studies since then have quoted mean prevalences of OSA of 27.3% in males (range 9–86%) and 22.5% in females (3.7–63.7%) and mean (range) prevalence of OSAHS of 6% (3–18%) in males and 4% (1–17%) in females [7, 8].

Consequently, and unsurprisingly, OSA/OSAHS has thus been considered a male disease, with male:female ratios ranging from 3:1 to 5:1 in the general population and from 8:1 to 10:1 in selected clinical populations [9]. Despite this, females now represent up to 40–50% of presentations at sleep clinics [10].

Clinical presentation
Failure to recognise the distinct clinical presentation and sex-specific differences in sleep studies may lead to underdiagnosis or misdiagnosis of OSA/OSAHS in females [11, 12].

Females are less likely to report snoring (males have higher snoring intensity by comparison [13]) or witnessed apnoeas. Females are more likely to complain of daytime fatigue, lack of energy, insomnia symptoms, morning headaches, mood disturbances and nightmares compared to males [11, 12].

This “atypical” clinical presentation at least partly explains the fact that female patients are diagnosed with OSA/OSAHS at older ages and with higher body mass index (BMI) than males [11, 12].

Females seem to have greater impairment of quality of life and higher healthcare expenditure compared to males with similar AHI levels [14–19]. In addition, females with OSA report a higher rate of impaired work performance, sick leave and divorce compared to females without OSA, identical in age and visceral fat mass; this kind of association has not been found among males [14–19].

OSA in females is associated with an increased risk of sickness absence compared to males with OSA, even 5 years versus 1 year prior to diagnosing OSA [20]. A prospective study of 74 543 cases of OSA from the Swedish Patient Register matched with 371 592 non-cases, demonstrated during a 5-year follow-up period a higher risk for disability pension among females with OSA compared to males with OSA [19].

Compared to males, OSA/OSAHS typically manifests in females as a lower AHI, shorter apnoeic episodes, lower proportion of supine OSA and clustering of apnoea during rapid eye movement (REM) sleep [11]. However, in females, the longest apnoeas are associated with a more severe oxygen desaturation [21].

Respiratory events during sleep are less frequently associated with complete upper airway collapse in females than in males [11]. However, despite less-severe OSA in terms of AHI, females are not less symptomatic compared to males, but report sleepiness at relatively low levels of AHI [22].

Therefore, especially in females, AHI alone is not a sufficient criterion for clinical severity of OSA. The severity should be specified with objective polysomnography (or cardiorespiratory polygraphy) findings (AHI/respiratory effort index plus flow-limitation) and subjective daytime sleepiness with functional disability. In females with low AHI, a continuous positive airway pressure (CPAP) trial should be symptom-driven [23, 24].

What might explain this apparent discrepancy between AHI and symptoms in females particularly? In females, upper airway obstruction often manifests as subcriterion events (snoring, flow limitation or prolonged partial upper airway obstruction) [25–28].

Arousals induce less ventilatory instability in females, thereby protecting them from OSA. Prolonged episodes of partial upper airway obstruction [25–28] typically appear in slow-wave sleep and are associated with increased carbon dioxide (CO2) levels [29–31]. Importantly, prolonged partial upper airway obstruction is far more common than “conventional” sleep apnoea in females [32]. Furthermore, hypothyroidism is more prevalent in females than in males, which per se may induce OSA.

Prolonged partial upper airway obstruction is related to increased respiratory resistance [33], which is characterised by increase in end-tidal CO2 [34] and transcutaneous CO2 [29, 30]. Prolonged partial obstruction with increased CO2 during sleep may contribute to a different symptom profile in females.

This is supported by the finding that in females, excessive daytime sleepiness and daytime fatigue associate with habitual snoring independent of AHI, age, obesity, smoking or sleep parameters [26]. Correction of prolonged flow limitation with CPAP treatment is associated with a higher attentiveness and a higher efficiency in normalising daytime vigilance than when eliminating only apnoea, hypopnoea and snoring [35].

Hypercapnia is associated with electroencephalogram (EEG) slowing and daytime sleepiness in OSA [36], and CPAP treatment corrects the EEG slowing and alleviates daytime sleepiness [37].

Pathophysiology of OSA in females

The different OSA prevalence between males and females has generated interest in sex-related aspects of OSA pathophysiology. The topic is complex, encompassing anatomical and physiological features of the upper airways, the modulating effects of sex hormones on control of breathing, and sex-dependent features of fat distribution in obesity [66].

Animal models have been developed, allowing to assess sex-related differences in sleep structure [67] and acquisition of phenotypes during early development. Moreover, recent work in animal models focused on the complex action of sex steroids, not only in control of breathing, but also regarding the protective action of oestrogen against oxidative stress [68].

Anatomy of the upper airways

Upper airway dimensions are normally larger in males than in females, but similar when normalised for body size [69]. Smaller dimensions should promote collapsibility of the airways in females compared to males, but this is not the case [70].

Upper airway length was found to be higher in males than in females, and associated with higher airway collapsibility [70]. Differences between sexes in airway length are not present in the prepubertal period, but become evident in post-pubertal girls and boys, suggesting a major effect of sex hormones [71]. Upper airway length correlates with OSA severity assessed as AHI [72], and is modified by ageing, with lengthening of upper airways especially in females [73], possibly secondary to increased laxity of soft tissues [74].

Physiology of the upper airways

In OSA patients, upper airway collapsibility under passive conditions (critical closing pressure, Pcrit) was consistently shown to be lower in females than in males [75, 76], while no sex-related difference was found in respiratory stability during sleep, evaluated as loop gain [75].

However, data on the relationship between adiposity, assessed as BMI (kg·m−2), and Pcrit differed between studies, since the slope of the relationship was similar in males and females in one study [75], and was markedly lower in females compared to males in another study of a larger sample [76].

The higher Pcrit in males is believed to be secondary to anatomical factors, i.e. longer upper airways as previously discussed, and differences in fat distribution, since females, especially in the pre-menopausal phase, show a peripheral rather than the central pattern distribution typical of males, with lower fat deposition around the upper airways and a smaller neck circumference for a similar BMI [77].

Ventilation during sleep is similarly regulated in healthy males and females [78, 79]. However, ventilation and upper airway function in females are physiologically modulated by sex hormones. Progesterone stimulates ventilation especially when associated with oestrogen [80].

Upper airway dilator muscle function at baseline and during application of an inspiratory load during wakefulness increased in normal females during the luteal compared to the follicular phase [81].

In females without OSA, upper airway resistance during sleep was lower in the luteal compared to the follicular phase, in agreement with a “protective” effect of progesterone [82]. However, the response to inspiratory muscle loading during sleep was not accompanied by increased upper airway dilator muscle activity in normal females compared to normal males [83].

More recent data showed that compensatory responses to prolonged upper airway obstruction during non-REM sleep were more effective in obese females than in obese males [84].

Several factors may account for such differences, including a lower airflow demand secondary to lower metabolic rate in females, differences in ventilatory timing responses to obstructed upper airways [85], lower chemoresponsiveness [86] or ventilatory response to arousal [87, 88].

In addition, experimental studies in rodents suggest that females are more resistant to the detrimental effects of chronic intermittent hypoxia, an effect possibly mediated by oestrogens [89, 90]. Although some controversies still exist due to species-dependent differences [91], recent human studies suggested a role of leptin in the modulation of neural compensatory mechanisms at the upper airway level [92].

Since plasma levels of leptin are higher in females, leptin represents a potential protective factor in obese females against upper airway obstruction, possibly acting at multiple levels. The therapeutic use of intranasal leptin has been successfully tested in obese animals [93].

Recent data indicate that expression of oestrogen receptor-α is decreased in the upper airway muscles of males with OSA compared to controls, possibly contributing to changes in muscle fibre types in OSA. However, no similar data in females have been collected thus far [94].

In summary, upper airways in females are less collapsible and more stable during sleep than in males, through a variety of mechanisms which involve sex hormones but are not limited to them. More efficient active responses of upper airways during respiratory events, different body fat distribution and lower instability of respiratory drive after arousals probably contribute to the lower susceptibility to respiratory events during non-REM sleep in females.

Currently, there are large efforts to physiologically phenotype OSA patients in order to personalise treatment [95]. To date, the question whether specific physiological phenotypes occur in females with OSA remains unanswered, and deserves further study.

The role of hormone replacement therapy

Approximately 25 years ago, sex steroid-based hormone replacement therapy (HRT) was no longer prescribed worldwide because of the negative results of randomised controlled trials showing that oestrogen did not confer protection against cardiovascular disease and might increase the risk of breast cancer [96].

More recently, a protective effect of oestrogen-based HRT has emerged, especially in females starting treatment early in the perimenopausal period, whereas treatment initiation at a later time did not confer any benefit [96].

As far as sleep disordered breathing is concerned, the possible protective role of HRT in post-menopausal females with OSA was assessed in studies involving small numbers of subjects.

In females without symptoms of sleep disordered breathing, respiratory events during sleep were few and unaffected by oestrogen replacement therapy [97], while treatment with medroxyprogesterone acetate (MPA) improved the inspiratory flow pattern in females with airflow limitation during sleep [49, 98].

In females with OSA, the effects of HRT have been controversial. One study found no effect of MPA 30 mg·day−1 [99]. Another study reported improved breathing during sleep after progestin and oestrogen HRT in females with mild OSAS in post-surgical menopause [100]. Cistulli et al. [101] found a decrease in AHI in REM sleep after HRT, while another study reported decreased AHI after treatment with oestrogens in post-menopausal females with moderate OSAS [102].

More recently, a randomised controlled trial in post-menopausal females with OSA treated with MPA after discontinuing CPAP for a few weeks showed no protective effects of MPA against respiratory events during sleep [103].

Metabolic changes

Females have a different fat distribution pattern compared to males [104]. Adipose tissue tends to be peripherally distributed in females, and centrally distributed in males, with a higher percentage of visceral fat in males compared to females with a similar BMI.

Such differences reflect a role of sex hormones during the fertile age [105], tending to disappear after the menopause, and may influence the prevalence and severity of OSA in females. It has long been known that females are usually more obese than males for a similar level of OSA severity and OSA can be predicted by visceral abdominal fat in males, and by peripheral and total fat in females [106–109].

The metabolic syndrome (MetS), a cluster of risk factors for visceral obesity and insulin resistance, is often associated with OSA in both sexes [110]. In patients with MetS and OSA, the anthropometric markers of obesity appear to be similar in males and females [111].

Finally, a recent study in young morbidly obese females awaiting bariatric surgery found that the waist-to-hip ratio was the best single predictor of AHI, even though it accounted for only 20% of total variance [112]. Therefore, menopausal status and degree of obesity interact variably in determining adipose tissue distribution and metabolic variables in females, and probably affect OSA prevalence.

The literature on OSA-associated metabolic changes does not provide satisfactory data to explore whether females show particular metabolic changes compared to males. This reflects the predominance of males in patient cohorts, and the fact that data analysis is usually adjusted for age, sex and BMI, which are the variables of interest in studies on OSA according to sex.

Conversely, studies in females indicate a similar relationship between altered glucose metabolism and OSA severity as in males [113]. Females show a high frequency of respiratory events exclusively in REM sleep [114].

In diabetic patients, derangement in glycaemic control was associated only with AHI in REM, possibly due to the increased sympathetic activity typical of this sleep phase [115].

According to these data, females may be at relatively higher risk of OSA-associated glucose disturbances compared to males, despite an overall AHI which is lower than in males. To date, no study has tested such a hypothesis. In relatively young (mean age 37 years), overweight/obese subjects without comorbidities other than well-controlled hypertension or hypothyroidism, insulin resistance was documented in males, but not in females with OSA [44], in agreement with the more favourable metabolic pattern associated with peripheral distribution of adipose tissue.

In summary, knowledge on whether metabolic aspects of OSA show differences between males and females is still rather limited. Sex-related differences in adipose tissue distribution are well known, and are probably involved in both upper airway function and metabolism. Such differences tend to disappear after menopause.


Source:
AASM

References

  1. Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J 2009; 33: 907–914.
  2. American Academy of Sleep Medicine (AASM). International Classification of Sleep Disorders, Third Edition: Diagnostic and Coding Manual. Darien, IL, AASM, 2014.
  3. Riha RL. Diagnostic approaches to respiratory sleep disorders. J Thorac Dis 2015; 7: 1373–1384.
  4. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–545.
  5. Johns MW. Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the Epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 2000; 9: 5–11.
  6. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–1235.
  7. Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population – a review on the epidemiology of sleep apnea. J Thorac Dis 2015; 7: 1311–1322.
  8. Theorell-Haglöw J, Miller CB, Bartlett DJ, et al. Gender differences in obstructive sleep apnoea, insomnia and restless legs syndrome in adults – what do we know? A clinical update. Sleep Med Rev 2018; 38: 28–38.
  9. Wimms A, Woehrle H, Ketheeswaran S, et al. Obstructive sleep apnea in women: specific issues and interventions. Biomed Res Int 2016; 2016: 1764837.
  10. Franklin KA, Sahlin C, Stenlund H, et al. Sleep apnoea is a common occurrence in females. Eur Respir J 2013; 41: 610–615
  11. Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 1: clinical features. Sleep 2002; 25: 412–419.
  12. Sforza E, Chouchou F, Collet P, et al. Sex differences in obstructive sleep apnoea in an elderly French population. Eur Respir J 2011; 37: 1137–1143.
  13. Levartovsky A, Dafna E, Zigel Y, et al. Breathing and snoring sound characteristics during sleep in adults. J Clin Sleep Med 2016; 12: 375–384.
  14. Greenberg-Dotan S, Reuveni H, Simon-Tuval T, et al. Gender differences in morbidity and health care utilization among adult obstructive sleep apnea patients. Sleep 2007; 30: 1173–1180.
  15. Gabbay IE, Lavie P. Age- and gender-related characteristics of obstructive sleep apnea. Sleep Breath 2012; 16: 453–460.
  16. Sjösten N, Kivimäki M, Oksanen T, et al. Obstructive sleep apnoea syndrome as a predictor of work disability. Respir Med 2009; 103: 1047–1055.
  17. Rod NH, Kjeldgård L, Åkerstedt T, et al. Sleep apnea, disability pensions, and cause-specific mortality: a Swedish nationwide register linkage study. Am J Epidemiol 2017; 186: 709–718.
  18. Tasbakan MS, Gunduz C, Pirildar S, et al. Quality of life in obstructive sleep apnea is related to female gender and comorbid insomnia. Sleep Breath 2018; 22: 1013–1020.
  19. Grunstein RR, Stenlöf K, Hedner JA, et al. Impact of self-reported sleep-breathing disturbances on psychosocial performance in the Swedish Obese Subjects (SOS) Study. Sleep 1995; 18: 635–643
  20. Sjösten N, Vahtera J, Salo P, et al. Increased risk of lost workdays prior to the diagnosis of sleep apnea. Chest 2009; 136: 130–136.
  21. Kulkas A, Duce B, Leppänen T, et al. Gender differences in severity of desaturation events following hypopnea and obstructive apnea events in adults during sleep. Physiol Meas 2017; 38: 1490–1502.
  22. Young T, Hutton R, Finn L, et al. The gender bias in sleep apnea diagnosis. Are women missed because they have different symptoms? Arch Intern Med 1996; 156: 2445–2451.
  23. Svensson M, Franklin KA, Theorell-Haglöw J, et al. Daytime sleepiness relates to snoring independent of the apnea-hypopnea index in women from the general population. Chest 2008; 134: 919–924.
  24. McNicholas WT, Bonsignore MR, Lévy P, et al. Mild obstructive sleep apnoea: clinical relevance and approaches to management. Lancet Respir Med 2016; 4: 826–834.
  25. Polo-Kantola P, Rauhala E, Helenius H, et al. Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy. Obstet Gynecol 2003; 102: 68–75.
  26. Anttalainen U, Saaresranta T, Kalleinen N, et al. Gender differences in age and BMI distributions in partial upper airway obstruction during sleep. Respir Physiol Neurobiol 2007; 159: 219–226.
  27. Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993; 104: 781–787
  28. Mohsenin V. Gender differences in the expression of sleep-disordered breathing: role of upper airway dimensions. Chest 2001; 120: 1442–1447.
  29. Rauhala E, Himanen SL, Saastamoinen A, et al. Prolonged spiking in the Emfit sensor in patients with sleep-disordered breathing is characterized by increase in transcutaneous carbon dioxide. Physiol Meas 2007; 28: 1163–1173.
  30. Rimpilä V, Saaresranta T, Huhtala H, et al. Transcutaneous CO2 plateau as set-point for respiratory drive during upper airway flow-limitation. Respir Physiol Neurobiol 2014; 191: 44–51.
  31. Himanen SL, Martikkala L, Sulkamo S, et al. Prolonged partial obstruction during sleep is a NREM phenomenon. Respir Physiol Neurobiol 2018; 255: 43–49.
  32. Anttalainen U, Saaresranta T, Kalleinen N, et al. CPAP adherence and partial upper airway obstruction during sleep. Sleep Breath 2007; 11: 171–176.
  33. Polo O, Brissaud L, Fraga J, et al. Partial upper airway obstruction in sleep after uvulopalatopharyngoplasty. Arch Otolaryngol Head Neck Surg 1989; 115: 1350–1354.
  34. Calero G, Farre R, Ballester E, et al. Physiological consequences of prolonged periods of flow limitation in patients with sleep apnea hypopnea syndrome. Respir Med 2006; 100: 813–817.
  35. Meurice JC, Paquereau J, Denjean A, et al. Influence of correction of flow limitation on continuous positive airway pressure efficiency in sleep apnoea/hypopnoea syndrome. Eur Respir J 1998; 11: 1121–1127.
  36. Wang D, Piper AJ, Yee BJ, et al. Hypercapnia is a key correlate of EEG activation and daytime sleepiness in hypercapnic sleep disordered breathing patients. J Clin Sleep Med 2014; 10: 517–522
  37. Morisson F, Décary A, Petit D, et al. Daytime sleepiness and EEG spectral analysis in apneic patients before and after treatment with continuous positive airway pressure. Chest 2001; 119: 45–52.
  38. Gouveris H, Bahr K, Jahn C, et al. The apnea-hypopnea index underestimates systemic inflammation in women with sleep-disordered breathing. J Womens Health 2018; 27: 920–926.
  39. Ljunggren M, Lindberg E, Franklin KA, et al. Obstructive sleep apnea during rapid eye movement sleep is associated with early signs of atherosclerosis in women. Sleep 2018; 41: zsy099.
  40. Strausz S, Havulinna AS, Tuomi T, et al. Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. BMJ Open 2018; 8: e022752.
  41. Anttalainen U, Grote L, Fietze I, et al. Insomnia symptoms combined with nocturnal hypoxia associate with cardiovascular comorbidity in the European sleep apnoea cohort (ESADA). Sleep Breath 2019; 23: 805–814.
  42. Saaresranta T, Hedner J, Bonsignore MR, et al. Clinical phenotypes and comorbidity in European sleep apnoea patients. PLoS One 2016; 11: e0163439
  43. Geovanini GR, Wang R, Weng J, et al. Association between obstructive sleep apnea and cardiovascular risk factors: variation by age, sex, and race. The Multi-Ethnic Study of Atherosclerosis. Ann Am Thorac Soc 2018; 15: 970–977.
  44. Temple KA, Leproult R, Morselli L, et al. Sex differences in the impact of obstructive sleep apnea on glucose metabolism. Front Endocrinol 2018; 9: 376.
  45. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163: 608–613.
  46. Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2003; 167: 1181–1185.
  47. Anttalainen U, Saaresranta T, Aittokallio J, et al. Impact of menopause on the manifestation and severity of sleep-disordered breathing. Acta Obstet Gynecol Scand 2006; 85: 1381–1388.Rowley JA, 
  48. Zhou XS, Diamond MP, et al. The determinants of the apnea threshold during NREM sleep in normal subjects. Sleep 2006; 29: 95–103.
  49. Saaresranta T, Aittokallio T, Polo-Kantola P, et al. Effect of medroxyprogesterone on inspiratory flow shapes during sleep in postmenopausal women. Respir Physiol Neurobiol 2003; 134: 131–143.
  50. Gao CC, Kapoor E, Lipford MC, et al. Association of vasomotor symptoms and sleep apnea risk in midlife women. Menopause 2018; 25: 391–398.
  51. Huang T, Lin BM, Redline S, et al. Type of menopause, age at menopause, and risk of developing obstructive sleep apnea in postmenopausal women. Am J Epidemiol 2018; 187: 1370–1379.
  52. LoMauro A, Aliverti A. Respiratory physiology of pregnancy: physiology masterclass. Breathe 2015; 11: 297–301
  53. Tan EK, Tan EL. Alterations in physiology and anatomy during pregnancy. Best Pract Res Clin Obstet Gynaecol 2013; 27: 791–802.
  54. Izci-Balserak B, Keenan BT, Corbitt C, et al. Changes in sleep characteristics and breathing parameters during sleep in early and late pregnancy. J Clin Sleep Med 2018; 14: 1161–1168.
  55. Dunietz GL, Shedden K, Schisterman EF, et al. Associations of snoring frequency and intensity in pregnancy with time-to-delivery. Paediatr Perinat Epidemiol 2018; 32: 504–511.
  56. Salameh M, Lee J, Palomaki G, et al. Snoring and markers of fetal and placental wellbeing. Clin Chim Acta 2018; 485: 139–143.
  57. Louis JM, Koch MA, Reddy UM, et al. Predictors of sleep-disordered breathing in pregnancy. Am J Obstet Gynecol 2018; 218: 521.e1–521.e12.
  58. Warland J, Dorrian J, Morrison JL, et al. Maternal sleep during pregnancy and poor fetal outcomes: a scoping review of the literature with meta-analysis. Sleep Med Rev 2018; 41: 197–219.
  59. Kahal H, Kyrou I, Tahrani AA, et al. Obstructive sleep apnoea and polycystic ovary syndrome: a comprehensive review of clinical interactions and underlying pathophysiology. Clin Endocrinol 2017; 87: 313–319.
  60. Kahal H,Kyrou I, Uthman O, et al. The association between obstructive sleep apnea and metabolic abnormalities in women with polycystic ovary syndrome: a systematic review and meta-analysis. Sleep 2018; 41: zsy085
  61. Tasali E, Chapotot F, Leproult R, et al. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 365–374.
  62. Miras AD, Kamocka A, Patel D, et al. Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surg Obes Relat Dis 2018; 14: 1033–1040.Gasa M, 
  63. Salord N, Fortuna AM, et al. Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur Respir J 2011; 38: 1089–1097.
  64. Llanos OL, Galiatsatos P, Guzmán-Vélez E, et al. Pharyngeal collapsibility during sleep is elevated in insulin-resistant females with morbid obesity. Eur Respir J 2016; 47: 1718–1726.
  65. Salord N, Fortuna AM, Monasterio C, et al. A randomized controlled trial of continuous positive airway pressure on glucose tolerance in obese patients with obstructive sleep apnea. Sleep 2016; 39: 35–41.Lozo T, 
  66. Komnenov D, Badr MS, et al. Sex differences in sleep disordered breathing in adults. Respir Physiol Neurobiol 2017; 245: 65–75.Mong JA, 
  67. Cusmano DM. Sex differences in sleep: impact of biological sex and sex steroids. Philos Trans R Soc Lond B Biol Sci 2016; 371: 20150110.
  68. Boukari R, Laouafa S, Ribon-Demars A, et al. Ovarian steroids act as respiratory stimulant and antioxidant against the causes and consequences of sleep-apnea in women. Respir Physiol Neurobiol 2017; 239: 46–54.Brown IG, 
  69. Zamel N, Hoffstein V. Pharyngeal cross-sectional area in normal men and women. J Appl Physiol 1986; 61: 890–895.
  70. Malhotra A, Huang Y, Fogel RB, et al. The male predisposition to pharyngeal collapse: importance of airway length. Am J Respir Crit Care Med 2002; 166: 1388–1395.
  71. Ronen O, Malhotra A, Pillar G. Influence of gender and age on upper-airway length during development. Pediatrics 2007; 120: e1028–e1034.
  72. Segal Y, Malhotra A, Pillar G. Upper airway length may be associated with the severity of obstructive sleep apnea syndrome. Sleep Breath 2008; 12: 311–316
  73. Malhotra A, Huang Y, Fogel R, et al. Aging influences on pharyngeal anatomy and physiology: the predisposition to pharyngeal collapse. Am J Med 2006; 119: 72.e9–72.e14
  74. Shigeta Y, Ogawa T, Venturin J, et al. Gender- and age-based differences in computerized tomographic measurements of the oropharynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 563–570.Jordan AS, 
  75. Wellman A, Edwards JK, et al. Respiratory control stability and upper airway collapsibility in men and women with obstructive sleep apnea. J Appl Physiol 2006; 99: 2020–2027
  76. Kirkness JP, Schwartz AR, Schneider H, et al. Contribution of male sex, age, and obesity to mechanical instability of the upper airway during sleep. J Appl Physiol 2008; 104: 1618–1624.
  77. Schwartz AR, Patil SP, Squier S, et al. Obesity and upper airway control during sleep. J Appl Physiol 2010; 108: 430–435.
  78. White DP, Weil JV, Zwillich CW. Metabolic rate and breathing during sleep. J Appl Physiol 1985; 59: 384–391.
  79. Douglas NJ, White DP, Pickett CK, et al. Respiration during sleep in normal man. Thorax 1982; 37: 840–844.Regensteiner JG, 
  80. Woodard WD, Hagerman DD, et al. Combined effects of female hormones and metabolic rate on ventilatory drives in women. J Appl Physiol 1989; 66: 808–813.
  81. Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 1998; 84: 1055–1062.Driver HS, 
  82. McLean H, Kumar DV, et al. The influence of the menstrual cycle on upper airway resistance and breathing during sleep. Sleep 2005; 28: 449–456.Pillar G, 
  83. Malhotra A, Fogel R, et al. Airway mechanics and ventilation in response to resistive loading during sleep. Influence of gender. Am J Respir Crit Care Med 2000; 162: 1627–1632.
  84. Chin CH, Kirkness JP, Patil SP, et al. Compensatory responses to upper airway obstruction in obese apneic men and women. J Appl Physiol 2012; 112: 403–410.
  85. Schneider H, Krishnan V, Pichard LE, et al. Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation. Eur Respir J 2009; 33: 1068–1076.
  86. Zhou XS, Shahabuddin S, Zahn BR, et al. Effect of gender on the development of hypocapnic apnea/hypopnea during NREM sleep. J Appl Physiol 2000; 89: 192–199
  87. Jordan AS, Eckert DJ, Catcheside PG, et al. Ventilatory response to brief arousal from non-rapid eye movement sleep is greater in men than in women. Am J Respir Crit Care Med 2003; 168: 1512–1519.
  88. Jordan AS, McEvoy RD, Edwards JK, et al. The influence of gender and upper airway resistance on the ventilatory response to arousal in obstructive sleep apnoea in humans. J Physiol 2004; 558: 993–1004.
  89. O’Halloran KD, Lewis P, McDonald F. Sex, stress and sleep apnoea: decreased susceptibility to upper airway muscle dysfunction following intermittent hypoxia in females. Respir Physiol Neurobiol 2017; 245: 76–82.
  90. Laouafa S, Ribon-Demars A, Marcouiller F, et al. Estradiol protects against cardiorespiratory dysfunctions and oxidative stress in intermittent hypoxia. Sleep 2017; 40: zxs104.
  91. Imayama I, Prasad B. Role of leptin in obstructive sleep apnea. Ann Am Thorac Soc 2017; 14: 1607–1621.
  92. Shapiro SD, Chin CH, Kirkness JP, et al. Leptin and the control of pharyngeal patency during sleep in severe obesity. J Appl Physiol 2014; 116: 1334–1341.
  93. Berger S, Pho H, Fleury-Curado T, et al. Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity. Am J Respir Crit Care Med 2019; 199: 773–783.
  94. Chen HH, Lu J, Guan YF, et al. Estrogen/ERR-α signaling axis is associated with fiber-type conversion of upper airway muscles in patients with obstructive sleep apnea hypopnea syndrome. Sci Rep 2016; 6: 27088.
  95. Bonsignore MR, Suarez Giron MC, Marrone O, et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 2017; 26: 170069.Lobo RA, 
  96. Pickar JH, Stevenson JC, et al. Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016; 254: 282–290.Polo-Kantola P, 
  97. Erkkola R, Irjala K, et al. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril 1999; 71: 873–880.
  98. Saaresranta T, Polo-Kantola P, Rauhala E, et al. Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep. Eur Respir J 2001; 18: 989–995.
  99. Block AJ, Wynne JW, Boysen PG, et al. Menopause, medroxyprogesterone and breathing during sleep. Am J Med 1981; 70: 506–510.
  100. Pickett CK, Regensteiner JG, Woodard WD, et al. Progestin and estrogen reduce sleep-disordered breathing in postmenopausal women. J Appl Physiol 1989; 66: 1656–1661
  101. Cistulli PA, Barnes DJ, Grunstein RR, et al. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax 1994; 49: 699–702.
  102. Manber R, Kuo TF, Cataldo N, et al. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep 2003; 26: 163–168.
  103. Anttalainen U, Saaresranta T, Vahlberg T, et al. Short-term medroxyprogesterone acetate in postmenopausal women with sleep-disordered breathing: a placebo-controlled, randomized, double-blind, parallel-group study. Menopause 2014; 21: 361–368.
  104. White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta 2014; 1842: 377–392.
  105. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gender Med 2009; 6: Suppl. 1, 60–75.
  106. Kritikou I, Basta M, Tappouni R, et al. Sleep apnoea and visceral adiposity in middle-aged male and female subjects. Eur Respir J 2013; 41: 601–609.
  107. Lubrano C, Saponara M, Barbaro G, et al. Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One 2012; 7: e47059.
  108. Harada Y, Oga T, Chihara Y, et al. Differences in associations between visceral fat accumulation and obstructive sleep apnea by sex. Ann Am Thorac Soc 2014; 11: 383–391.
  109. Simpson L, Mukherjee S, Cooper MN, et al. Sex differences in the association of regional fat distribution with the severity of obstructive sleep apnea. Sleep 2010; 33: 467–474
  110. Gaines J, Vgontzas AN, Fernandez-Mendoza J, et al. Obstructive sleep apnea and the metabolic syndrome: the road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment. Sleep Med Rev 2018; 42: 211–219
  111. Mazzuca E, Battaglia S, Marrone O, et al. Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. J Sleep Res 2014; 23: 13–21
  112. Gasa M, López-Padrós C, Monasterio C, et al. Anthropometrical phenotypes are important when explaining obstructive sleep apnea in female bariatric cohorts. J Sleep Res 2019: e12830.
  113. Theorell-Haglöw J, Berne C, Janson C, et al. Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. Eur Respir J 2008; 31: 1054–1060.
  114. Koo BB, Patel SR, Strohl K, et al. Rapid eye movement-related sleep-disordered breathing.: influence of age and gender. Chest 2008; 134: 1156–1161.
  115. Grimaldi D, Beccuti G, Touma C, et al. Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. Diabetes Care 2014; 37: 355–363.
  116. Jayaraman G, Majid H, Surani S, et al. Influence of gender on continuous positive airway pressure requirements in patients with obstructive sleep apnea syndrome. Sleep Breath 2011; 15: 781–784
  117. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014; 383: 736–747.
  118. Isetta V, Montserrat JM, Santano R, et al. Novel approach to simulate sleep apnea patients for evaluating positive pressure therapy devices. PLoS One 2016; 11: e0151530.
  119. McArdle N, King S, Shepherd K, et al. Study of a novel APAP algorithm for the treatment of obstructive sleep apnea in women. Sleep 2015; 38: 1775–1781.
  120. Eckert DJ. Phenotypic approaches to obstructive sleep apnoea – new pathways for targeted therapy. Sleep Med Rev 2018; 37: 45–59.
  121. Wray CM, Thaler ER. Hypoglossal nerve stimulation for obstructive sleep apnea: a review of the literature. World J Otorhinolaryngol Head Neck Surg 2016; 2: 230–233.
  122. Garg RK, Afifi AM, Sanchez R, et al. Obstructive sleep apnea in adults: the role of upper airway and facial skeletal surgery. Plast Reconstr Surg 2016; 138: 889–898.
  123. Marklund M, Stenlund H, Franklin KA. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest 2004; 125: 1270–1278.
  124. Vecchierini MF, Attali V, Collet JM, et al. Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. Sleep Breath 2019; 23: 837–848.
  125. Newman AB, Foster G, Givelber R, et al. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005; 165: 2408–2413.
  126. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep 2013; 36: 641–649A

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.